rabbit polyclonal antibody against ddr2 (GeneTex)
Structured Review

Rabbit Polyclonal Antibody Against Ddr2, supplied by GeneTex, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/rabbit polyclonal antibody against ddr2/product/GeneTex
Average 90 stars, based on 1 article reviews
Images
1) Product Images from "Discoidin Domain Receptor 2 Contributes to Breast Cancer Progression and Chemoresistance by Interacting with Collagen Type I"
Article Title: Discoidin Domain Receptor 2 Contributes to Breast Cancer Progression and Chemoresistance by Interacting with Collagen Type I
Journal: Cancers
doi: 10.3390/cancers16244285
Figure Legend Snippet: Representative image of DDR2 and collagen type I immunostaining in human breast cancer. ( A – C ): immunostaining of DDR2 in breast cancer cells ( A ), normal breast epithelium ( B ), and human heart as a positive control of DDR2 ( C ). ( D – F ): immunostaining of collagen type I in cancerous stroma ( D ), normal breast stroma ( E ), and human skin as a positive control of collagen type I ( F ). Bar = 100 µm, respectively.
Techniques Used: Immunostaining, Positive Control
Figure Legend Snippet: Association between DDR2 status and clinicopathological factors in 224 breast carcinomas.
Techniques Used:
Figure Legend Snippet: Association between DDR2 status and clinicopathological factors according to collagen type I status in 224 breast carcinomas.
Techniques Used:
Figure Legend Snippet: Association between DDR2 status and clinical outcomes of breast cancer patients (n = 224). ( A – D ): disease-free survival ( A , C ) and breast cancer-specific survival ( B , D ) according to DDR2 status ( A , B ) or DDR2/collagen type I combination status ( C , D ). ( E – H ): disease-free survival according to DDR2 status ( E , F ) or DDR2/collagen type I combination status ( G , H ) in the patients who received chemotherapy ( E , G ) or not ( F , H ).
Techniques Used:
Figure Legend Snippet: Uni- and multivariate analysis of disease-free survival.
Techniques Used:
Figure Legend Snippet: The effect of DDR2 in the proliferation of human breast cancer cell lines in the presence of collagen type I. ( A ) Immunoblotting of exogenous DDR2 protein in MCF-7, MDA-MB-231, and T47D cells. ( B – D ): cell proliferation of MCF-7 ( A ), MDA-MB-231 ( B ), and T47D ( D ) transfected with an empty vector or DDR2-expressing vector in the absence or presence of collagen coating. ( E ) Immunoblotting of DDR2 in the cells transfected with siRNA against DDR2 (siDDR2-1, 2). ( F – H ): cell proliferation of MCF-7 ( F ), MDA-MB-231 ( G ), and T47D ( H ) transfected with siRNAs in the presence of collagen coating. * p < 0.05, ** p < 0.01, and *** p < 0.001 compared to the empty vector, respectively.
Techniques Used: Western Blot, Transfection, Plasmid Preparation, Expressing
Figure Legend Snippet: The effect of DDR2 on the resistance to epirubicin in the breast cancer cell lines. ( A – C ): viability of MCF-7 ( A ), MDA-MB-231 ( B ), and T47D ( C ) transfected with an empty vector or DDR2-expressing vector under epirubicin treatment (500 nM for MCF-7; 250 nM for MDA-MB-231 and T47D). These cells were plated onto collagen-coated culture plates. * p < 0.05, ** p < 0.01, and *** p < 0.001 compared to the empty vector, respectively. ( D – F ): viability of MCF-7 ( D ), MDA-MB-231 ( E ), and T47D ( F ) transfected with siRNA targeting DDR2 under epirubicin treatment. ( G , H ) mRNA and protein expression in chemosensitive parental cells and epirubicin-resistant cells ( G ; MCF-7 series, H ; MDA-MB-231 series). ** p < 0.01, respectively. ( I , J ) The effect of DDR2 inhibitor WRG-28 treatment (48 h) on the proliferation of chemosensitive parental cells and epirubicin-resistant cells ( F ; MCF-7 series, G ; MDA-MB-231 series).
Techniques Used: Transfection, Plasmid Preparation, Expressing
Figure Legend Snippet: The effect of DDR2 on the apoptosis of breast MCF-7 ( A ), MDA-MB-231 ( B ), and T47D ( C ). *** p < 0.001.
Techniques Used:
